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Summary
Background Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines 
at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the 
effect of Novartis Access in Kenya, the first country to receive the programme.
Methods We did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly 
assigned to the intervention or the control group with a covariate-constrained randomisation procedure that 
maximised balance on a set of demographic and health variables. In intervention counties, public and non-profit 
health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and 
Supplies (MEDS). Data were collected from all facilities served by MEDS and a sample of households in study 
counties. Households were eligible if they had at least one adult patient who had been diagnosed and prescribed 
medicines for one of the non-communicable diseases targeted by the programme: hypertension, heart failure, 
dyslipidaemia, type 2 diabetes, asthma, or breast cancer. Primary outcomes were availability and price of portfolio 
medicines at health facilities, irrespective of brand; and availability of medicines at patient households. Impacts were 
estimated with intention-to-treat analysis. This trial is registered with ClinicalTrials.gov (NCT02773095).
Findings On March 8, 2016, we randomly assigned eight clusters to intervention (four clusters; 74 health facilities; 
342 patients) or control (four clusters; 63 health facilities; 297 patients). 69 intervention and 58 control health facilities, 
and 306 intervention and 265 control patients were evaluated after a 15 month intervention period (last visit 
February 28, 2018). Novartis Access significantly increased the availability of amlodipine (adjusted odds ratio 
[aOR] 2·84, 95% CI 1·10 to 7·37; p=0·031) and metformin (aOR 4·78, 95% CI 1·44 to 15·86; p=0·011) at health 
facilities, but did not affect the availability of portfolio medicines overall (adjusted β [aβ] 0·05, 95% CI –0·01 to 0·10; 
p=0·096) or their price (aβ 0·48, 95% CI –1·12 to 0·72; p=0·500). The programme did not affect medicine availability 
at patient households (aOR 0·83, 95% CI 0·44 to 1·57; p=0·569).
Interpretation Novartis Access had little effect in its first year in Kenya. Access programmes operate within complex 
health systems and reducing the wholesale price of medicines might not always or immediately translate to improved 
patient access. The evidence generated by this study will inform Novartis’s efforts to improve their programme going 
forward. The study also contributes to the public evidence base on strategies for improving access to medicines 
globally.
Funding Sandoz International (a subsidiary of Novartis International).
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license. 
Introduction
The burden of non-communicable diseases is growing in 
low-income and middle-income countries, straining 
national health systems and compounding economic 
hardship.1 In Kenya, non-communicable diseases 
account for 27% of deaths among people between 
30 years of age and 70 years of age, most due to causes 
related to hypertension and diabetes.2 To address this 
burden, patients need to have reliable access to essential 
medicines to manage their conditions, among other 
strategies.3 In Kenya, patients with non-communicable 
disease face several barriers to access, often related to 
affordability and availability.4 Most of these patients in 
the country pay out of pocket for their medicines, and 
stockouts at public health facilities are frequent.5,6 These 
barriers dispro portionately affect the poorest patients, 
exacerbating health inequities.7
The Sustainable Development Goals include a target to 
reduce premature mortality from non-communicable 
diseases by a third by 2030.8 The UN has recognised private 
sector engagement as crucial to achieving the Sustainable 
Development Goals, following on from the explicit 
mention of the role of pharmaceutical companies in 
making essential medicines more affordable in developing 
countries in Target 8E of the Millennium Development 
Goals.9 The Lancet Commission on Essential Medicines for 
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Universal Health Coverage10 once again highlighted the 
role and responsibility of pharmaceutical companies in 
contributing to efforts to make medicines affordable 
globally. Within this context, Novartis has launched 
Novartis Access, a programme that provides low-cost 
medicines for non-communicable diseases in low-income 
and middle-income countries.11 Kenya was the first country 
to receive Novartis Access after an initial announce ment in 
2015. As part of the programme, a portfolio of medicines 
for treatment of hypertension, heart failure, dyslipidaemia, 
type 2 diabetes, asthma, and breast cancer was made 
available for purchase by the Mission for Essential Drugs 
and Supplies (MEDS), a main distributor to public and 
non-profit health facilities in Kenya, at a wholesale price of 
US$1 per treatment per month.
We did a cluster-randomised controlled trial to test the 
effect of Novartis Access on availability and price of non-
communicable disease medicines in eight counties in 
Kenya. Public and non-profit health facilities in counties 
randomised to receive the programme were allowed to 
purchase Novartis Access medicines from MEDS. Data 
were collected from health facilities and a sample of 
households in study counties at baseline and again after 
a 15 month intervention period. 
Methods
Study design and participants
The study was a cluster-randomised controlled trial 
implemented in eight counties in Kenya. Study counties 
were selected from 47 total counties in Kenya through a 
three-stage process. First, three counties were excluded 
due to security concerns. Second, 32 counties were 
excluded because they did not purchase a substantial 
volume (at least $100 000) of medicines from MEDS in 
the previous year and had little potential exposure to the 
programme. Third, four additional counties were 
excluded to eliminate shared borders in the final sample, 
to minimise the risk of contamination between inter-
vention and control counties. The eight counties included 
in the study were Embu, Kakamega, Kwale, Makueni, 
Narok, Nyeri, Samburu, and West Pokot.
All public and non-profit health facilities within the 
eight study counties served by MEDS were enrolled in 
the study. In Kenya, public sector medicine purchasing is 
managed at the county level, and in counties served by 
MEDS nearly all public health facilities from local 
dispensaries through county referral hospitals can 
purchase from MEDS. MEDS is also the main medicine 
supplier for the large network of non-profit health 
Research in context
Evidence before this study
In 2016, we conducted a systematic review to identify published 
evaluations of pharmaceutical industry-led access programmes in 
low-income and middle-income countries and to assess the 
quality of the available evidence on the effect of these 
programmes. First, we developed a list of industry-led access 
programmes by reviewing the Health Partnerships Directory of 
the International Federation of Pharmaceutical Manufacturers 
and Associations (IFPMA). Information from the directory was 
supplemented with information from reports published by the 
Access to Medicine Index and annual and corporate social 
responsibility reports for non-IFPMA companies. On May 1, 2016, 
we searched PubMed, Google Web, and Google Scholar for 
published evaluations of identified access programmes, using as 
search terms the name of the programme, the name of the 
company, the focus disease, and the focus countries. We did not 
set restrictions on the publication date of evaluations. 
We identified 120 access programmes that fit our criteria, seven 
of which had at least one published evaluation. We reviewed all of 
the published evaluations and assessed their quality using the 
GRADE system. None of the evaluations were rated as high 
quality and three were rated as moderate quality. We found no 
previous evaluations that used a randomised controlled trial 
design. None of the published evaluations provided clear 
evidence on the effect of a price reduction programme similar to 
Novartis Access.
Added value of this study
To our knowledge, this study is the first randomised controlled 
trial assessing the effect of a pharmaceutical industry-led 
access to medicines programme. We found that Novartis 
Access, a programme offering a portfolio of non-
communicable disease medicines at a wholesale price of US$1 
per treatment per month in Kenya, had little effect during its 
first year on the availability of medicines at facilities. Although 
the programme significantly increased the availability of 
amlodipine and metformin at health facilities, there was no 
effect on medicine prices or on availability at patient 
households. The study contributes to the public evidence base 
on strategies for improving access to non-communicable 
diseases medicines in low-income and middle-income 
countries. The study also contributes to ongoing discussions 
on the role of measurement and transparency in establishing 
accountability for private sector social programmes.
Implications of all the available evidence
Novartis Access is one of a growing number of 
pharmaceutical industry-led access programmes. Few of these 
programmes have been rigorously evaluated, and little is 
known about their effect or which strategies work best to 
improve access. This study suggests that offering a portfolio of 
medicines at a reduced price might not lead to immediate 
improvements in patient access. In order to build a more 
robust evidence base on this important topic and ensure 
accountability, rigorous measurement and transparent 
reporting should be adopted as a standard for pharmaceutical 
industry efforts to improve access to medicines globally. This 
study demonstrates that pharmaceutical companies can use 
robust, high-quality methods to evaluate their access 
programmes.
For the Mission for Essential 
Drugs and Supplies see 
http://www.meds.or.ke
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facilities in Kenya, and therefore nearly all non-profit 
facilities in study counties were enrolled. The final list of 
eligible facilities was confirmed by MEDS before the 
start of the study.
Households were randomly selected in two stages of 
sampling. In the first stage, 80 census enumeration areas 
(ten in each county) were randomly selected with 
probability proportional to population size on the basis of 
data from the most recent census. In the second stage, 
ten starting points were randomly chosen from within 
each enumeration area with Global Positioning System 
information on area boundaries from the most recent 
census.12 For each random starting point, the nearest 
household was visited and screened for eligibility. If 
found to be ineligible, the next nearest household to the 
left was visited and screened for eligibility. This process 
continued until an eligible household was found for each 
random starting point. In counties with a low prevalence 
of diag nosed non-communicable diseases, a small 
number of enumeration areas did not have ten eligible 
households. Additional enumeration areas were 
randomly selected in these counties with probability 
proportional to population size and the same household 
sampling procedure was followed. The aim was to enrol 
100 households in each county and 800 households in 
total at baseline. Eligible households were provided with 
study information as part of the informed consent 
procedure and decided whether to enrol at that time.
To be eligible for the study, a household had to have at 
least one permanent resident 18 years or older who had 
been diagnosed and prescribed medicines for one of the 
following non-communicable diseases: hypertension, 
heart failure, dyslipidaemia, type 2 diabetes, asthma, or 
breast cancer. The Novartis Access portfolio includes 
medicines to treat these diseases. Eligibility criteria were 
assessed through self-report at the time of recruitment. 
All who were eligible were recruited from households 
with multiple residents who met these criteria. Partici-
pants provided informed consent before study initiation. 
The study was approved by Institutional Review Boards 
at Strathmore University in Kenya (protocol number 
0042/16) and at Boston University in the United States 
(protocol number H-348730) before enrolment of 
participants.
Randomisation and masking
Counties (clusters) were randomised by the study team 
before baseline enrolment to either the intervention or 
the control group with a covariate-constrained random-
isation procedure13 that maximised balance on a set of 
demographic and health variables: total population, 
population density, proportion of the population in urban 
areas, poverty rate, number of health facilities, physicians 
per person, health spending per person, overall value 
ordered through MEDS in previous year, and proportion 
of value ordered through MEDS in previous year by 
private non-profit versus public health facilities. Group 
assignment was masked from data collectors. Participants 
were not told which group they were assigned to, 
although complete masking of participants was not 
possible.
Procedures
After baseline enrolment, Novartis Access was rolled out 
in intervention counties where public and non-profit 
health facilities were allowed to purchase programme 
medicines from MEDS. Table 1 presents the 14 non-
communicable disease medicines included in the Novartis 
Access portfolio. These medicines were packaged with 
programme-specific branding. Generic or originator forms 
of the same medicines produced by various manufacturers 
are available for purchase throughout Kenya. Novartis 
Access medicines were offered exclusively to MEDS 
throughout the study period, although conversations 
with the government purchaser (the Kenya Medical 
Supplies Authority [KEMSA]) about their inclusion in the 
programme were ongoing during this time. Private sector 
outlets were not allowed to purchase Novartis Access 
medicines during the study period. All groups maintained 
their ability to purchase standard Novartis and Sandoz 
products through previously established channels.
MEDS and KEMSA are the primary medicine suppliers 
for public and non-profit health facilities in Kenya, 
although facilities can purchase medicines not available 
through MEDS or KEMSA from other suppliers. For 
public facilities, medicine purchases are usually made 
through county health management teams14 while 
non-profit facilities purchase medicines directly from 
suppliers. Data on the relative market shares of MEDS 
and KEMSA are not publicly available. However, MEDS 
estimates that they supply roughly 40% of medicines by 
volume to public and non-profit facilities, with KEMSA 
accounting for most of the remaining supply (Mariana 
Mutwiri, personal communication, Oct 29, 2018).
For the Kenya Medical 
Supplies Authority see 
http://www.kemsa.co.ke
Medicine














The Novartis Access portfolio also includes one medicine not used for 
non-communicable diseases (amoxicillin, 250 mg dispersible), which was not 
analysed. *Treatment for hypertension only.
Table 1: Medicines included in the Novartis Access portfolio
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Surveys were administered at health facilities and 
households at baseline before implementation of 
Novartis Access (Sept 5–Oct 13, 2016) and after a 
15 month intervention period (Jan 22–Feb 23, 2018). 
Surveillance data on stock of Novartis Access-branded 
medicines were collected by assessors by calling the cell 
phone of a staff member at each health facility monthly 
from Dec 6, 2016, until Dec 19, 2017. Additionally, 
qualitative interviews were done at follow-up with staff at 
a randomly selected subsample of 27 facilities to better 
understand medicine procurement decisions and general 
awareness of the Novartis Access programme. Finally, 
Novartis provided information on the date of regulatory 
approval and the date of first importation for each 
Novartis Access medicine in Kenya.
Outcomes
The primary outcomes were medicine availability and 
price at health facilities, and medicine availability at 
households. Availability and price at health facilities were 
assessed for the 14 medicines included in the Novartis 
Access portfolio, and were measured for all branded and 
generic versions of those medicines. When a facility had 
more than one version of a medicine, the lowest price 
was used. Data on medicine stock and prices were 
collected during an unannounced visit by study assessors 
who interviewed dispensing staff and confirmed 
responses through direct observation of stock shelves. 
Availability was defined as having a medicine in stock on 
the day of the assessment, irrespective of whether the 
medicine was Novartis Access brand or how many units 
were available. Availability was analysed for individual 
medicines, and for a composite measure defined as the 
proportion of the 14 medicines available. Medicine prices 
were converted to median price ratios (MPRs) by dividing 
the observed price at the facility by the median supplier 
price reported in the 2015 International Medical Products 
Price Guide.15 Medicine prices were analysed for 
individual medicines and as a composite measure 
defined as the average value of the MPR for the medicines 
(of the 14) that were in stock on the day of the assessment. 
Medicine prices were captured in Kenyan shillings, while 
the most recent International Medical Products Price 
Guide median supplier prices are available in 2015 US$; 
before calculating MPRs, International Medical Products 
Price Guide prices were converted to Kenyan shillings 
and inflation adjusted to correspond to the first day of 
data collection for each survey round. This method was 
developed by WHO and Health Action International and 
has previously been validated in several low-income and 
middle-income countries.16
Household medicine availability was measured during 
unannounced home visits. Respondents were asked 
whether they had medicines in the home for treatment of 
their non-communicable disease, and those who 
indicated that they did were asked to show the medicines 
to the assessor for confirmation. For each confirmed 
medicine, assessors collected information on name, pack 
size, and dosage form, as well as price paid per pack. 
Medicine names were confirmed as non-communicable 
disease treatments during data cleaning. Participants 
with at least one confirmed medicine for treatment of 
their non-communicable disease were defined as having 
medicines available, irrespective of whether the medicine 
was Novartis Access brand or part of the programme 
portfolio. The study protocol identified household 
medicine prices and expenditures as primary outcomes. 
However, some respondents had difficulty recalling this 
information which led to substantial amounts of missing 
data. As a result, the study was underpowered on these 
outcomes and for this reason they were excluded from 
the analysis.
The household sample size was determined to provide 
statistical power to detect a ten percentage point increase 
in the probability of having a non-communicable disease 
medicine at home with α equal to 0·05, assuming eight 
clusters of equal size, 10% loss to follow-up, and an 
intracluster correlation coefficient of 0·05. The intracluster 
correlation assumption was similar to the one used in the 
ongoing LARK hypertension trial in Kenya17 and aligns 
with published estimates from recent studies among rural 
populations in the USA and Canada.18,19
Statistical analysis
First, we compared baseline characteristics of health 
facilities and household respondents in the intervention 
and control groups, and characterised attrition by 
treatment group. We then estimated the effect of the 
intervention on the primary outcomes of interest at 
For currency conversion see 
http://xe.com
For more on the 




Figure 1: Trial profile
8 clusters randomly allocated
4 clusters allocated to intervention4 clusters allocated to control
74 eligible facilities (342 eligible patients) enrolled at 
  baseline










 5 facilities lost to follow-up
 3 refused
 1 no longer operating
 1 not available




 9 not available
 5 facilities lost to follow-up
 1 refused
 3 no longer operating
 1 not available




 13 not available
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health facilities and households using an intention-
to-treat approach. For continuous outcome variables, 
hierarchical linear regression models with cluster 
random effects were fit using STATA’s xtreg package to 
estimate unadjusted and adjusted effects (β). For 
dichotomous outcome variables, we fitted hierarchical 
logistic regression models with cluster random effects 
using STATA’s melogit package to estimate unadjusted 
and adjusted odds ratios. Regression models were 
not fitted for individual medicines found at less than 
5% of facilities at follow-up. Data on availability of these 
medicines at baseline and follow-up are presented in the 
appendix, along with p values from Fisher’s exact tests 
comparing availability at follow-up.
All unadjusted models included controls for the outcome 












Lost to follow-up 
(n=5)
Level
Dispensary 40 (63%) 37 (64%) 3 (60%) 39 (53%) 38 (55%) 1 (20%)
Health centre 9 (14%) 8 (14%) 1 (20%) 17 (23%) 15 (22%) 2 (40%)
District hospital 13 (21%) 12 (21%) 1 (20%) 14 (19%) 12 (17%) 2 (40%)
County hospital 1 (2%) 1 (2%) 0 4 (5%) 4 (6%) 0
Public ownership 22 (35%) 22 (38%) 0 37 (50%) 36 (52%) 1 (20%)
Proportion of NCD medicines 
available*
0·14 (0·13) 0·14 (0·12) 0·10 (0·19) 0·20 (0·12) 0·19 (0·09) 0·34 (0·28)
Amlodipine 16 (25%) 15 (26%) 1 (20%) 22 (30%) 19 (28%) 3 (60%)
Furosemide 34 (54%) 33 (57%) 1 (20%) 62 (84%) 58 (84%) 4 (80%)
Hydrocholorothiazide 12 (19%) 11 (19%) 1 (20%) 16 (22%) 13 (19%) 3 (60%)
Metformin 30 (48%) 29 (50%) 1 (20%) 56 (76%) 52 (75%) 4 (80%)
Salbutamol 24 (38%) 23 (40%) 1 (20%) 35 (47%) 32 (46%) 3 (60%)
Average MPR† 2·94 (1·57) 2·82 (1·51) 5·20 (0·71) 2·78 (1·44) 2·65 (1·35) 4·11 (1·90)
Data are n (%) or mean (SD). NCD=non-communicable disease. There were too few observations in facilities lost to follow-up to estimate median price ratios (MPR). 
*Proportion of the following medicines in stock: amlodipine, anastrozole, bisoprolol, furosemide, glimepiride, hydrochlorothiazide, letrozole, metformin, ramipril, 
salbutamol, simvastatin, tamoxifen, valsartan, and vildagliptin. †Average MPR for amlodipine, anastrozole, bisoprolol, furosemide, glimepiride, hydrochlorothiazide, 
letrozole, metformin, salbutamol, simvastatin, and tamoxifen. Ramipril (available at two facilities), valsartan (available at two facilities), and vildagliptin (available at one 
facility) were excluded because they did not have a published median reference price.












Lost to follow-up 
(n=36)
Age (months), mean (SD) 57·9 (15·9) 58·1 (15·8) 55·0 (16·4) 58·9 (17·3) 59·2 (16·9) 57·1 (20·7)
Sex
Female 212 (71%) 190 (72%) 22 (69%) 228 (67%) 209 (68%) 19 (53%)
Male 85 (29%) 75 (28%) 10 (31%) 114 (33%) 97 (32%) 17 (47%)
Married 202 (68%) 180 (68%) 22 (69%) 244 (71%) 220 (72%) 24 (67%)
Completed primary school 140 (47%) 126 (48%) 14 (44%) 165 (48%) 145 (47%) 20 (56%)
Household wealth quintile, 
mean (SD)
3·0 (1·4) 3·0 (1·4) 2·7 (1·5) 3·0 (1·4) 3·0 (1·4) 3·0 (1·6)
NCD diagnosis
Hypertension 203 (68%) 184 (69%) 19 (59%) 242 (71%) 217 (71%) 25 (69%)
Diabetes 68 (23%) 57 (22%) 11 (34%) 74 (22%) 63 (21%) 11 (31%)
Asthma 57 (19%) 51 (19%) 6 (19%) 72 (21%) 66 (22%) 6 (17%)
Heart failure 10 (3%) 8 (3%) 2 (6%) 14 (4%) 11 (4%) 3 (8%)
Dyslipidaemia 0 0 0 2 (1%) 2 (1%) 0
Had medicine at home 196 (66%) 179 (68%) 17 (53%) 221 (65%) 199 (65%) 22 (61%)
NCD=non-communicable disease.
Table 3: Baseline characteristics of study patients
See Online for appendix
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analysis, adjusted models included the level of the health 
facility and whether it was public or non-profit as controls. 
For the household analysis, adjusted models included a set 
of baseline demographic variables: age, sex, marital status, 
education level, household size, and household wealth.
The main results are intention-to-treat estimates. As a 
robustness check, we did an as-treated analysis using 
county-level variation in the average number of Novartis 
Access medicine offerings per facility. Offerings were 
defined as the number of unique Novartis Access 
medicines available at a facility at the 15 month follow-up 
visit. As a second robustness check, we re-estimated 
household-level effect in the full study population with 
sampling weights and a finite population correction. 
Finally, we re-estimated household-level effects using 
linear probability models with cluster random effects to 
complement interpretation of the main results. All 
analyses were done with STATA version 14.
This trial was registered on ClinicalTrials.gov before 
baseline data collection (NCT02773095). The full study 
protocol was published before the start of baseline data 
collection.20
Role of the funding source
The funder had no role in study design, data collection 
and analysis, decision to publish, or preparation of the 
manuscript. The funding agreement is publicly available. 
The corresponding author had full access to all of the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Eight counties were randomly assigned to intervention 
(Kwale, Makueni, Nyeri, and West Pokot counties; 
74 facilities, 342 patients) or control (Embu, Kakamega, 
Narok, and Samburu counties; 63 facilities, 297 patients). 
Across the full study area, 7870 households were visited 
at baseline and screened for eligibility. At the 15 month 
follow-up (last visit Feb 28, 2018), 69 (93%) facilities and 
306 (89%) patients were retained in the intervention 
Control (n=58) Novartis Access 
(n=69)
ICC Unadjusted† Adjusted‡
OR (95% CI) p value OR (95% CI) p value
Amlodipine 18 (31%) 33 (48%) 0·06 2·45 (1·04–5·76) 0·041 2·84 (1·10–7·37) 0·031
Furosemide 42 (72%) 60 (87%) 0·11 1·51 (0·34–6·63) 0·588 1·74 (0·39–7·75) 0·468
Hydrocholorothiazide 40 (69%) 59 (86%) 0·21 2·28 (0·44–11·87) 0·327 2·72 (0·49–14·98) 0·251
Metformin 30 (52%) 56 (81%) 0·17 3·02 (1·08–8·48) 0·036 4·78 (1·44–15·86) 0·011
Salbutamol 30 (52%) 39 (57%) 0·01 1·12 (0·50–2·53) 0·785 1·12 (0·51–2·50) 0·772
Data are n (%) unless otherwise stated. All regression models include random effects for study clusters (ie, counties). ICC=intracluster correlation coefficient. OR=odds ratio. 
*Anastrozole, bisoprolol, glimepiride, letrozole, ramipril, simvastatin, tamoxifen, valsartan, and vildagliptin were found at three or fewer facilities at follow-up and were not 
analysed for impact. A summary of availability for those medicines is provided in the appendix. †Controlling for baseline value of the outcome. ‡Controlling for baseline value 
of the outcome, facility level, and public ownership.
Table 4: Effect of Novartis Access on number of facilities with medicines available*
Control (n=265) Novartis Access 
(n=306)
ICC Unadjusted* Adjusted†
β (95% CI) p value β (95% CI) p value
Proportion of NCD 
medicines available‡
20% (13%) 27% (11%) 0·17 0·04 (–0·04 to 0·12) 0·294 0·05 (–0·01 to 0·10) 0·096
MPR
Average for NCD 
medicines§
2·78 (1·41) 2·85 (1·68) 0·02 0·27 (–0·78 to 1·32) 0·614 0·48 (–0·92 to 1·88) 0·500
Amlodipine 2·64 (1·76) 2·36 (1·30) 0·05 –0·75 (–2·71 to 1·22) 0·457 –0·20 (–1·12 to 0·72) 0·670
Furosemide 3·59 (2·28) 3·54 (2·32) 0·15 –0·25 (–2·30 to 1·80) 0·812 0·27 (–1·92 to 2·46) 0·812
Hydrochlorothiazide 4·61 (3·02) 4·50 (3·02) 0·17 –0·40 (–3·22 to 2·42) 0·780 0·15 (–2·24 to 2·55) 0·899
Metformin 2·69 (1·57) 2·76 (2·20) 0·13 0·42 (–0·96 to 1·81) 0·548 0·53 (–0·39 to 1·46) 0·260
Salbutamol 1·31 (0·44) 1·17 (0·32) 0·19 –0·20 (–0·59 to 0·20) 0·330 –0·12 (–0·39 to 0·15) 0·371
Data are mean (SD) unless otherwise stated. All regression models include random effects for study clusters (ie, counties). ICC=intracluster correlation coefficient. 
NCD=non-communicable disease. MPR=median price ratio. *Controlling for baseline value of the outcome. †Controlling for baseline value of the outcome, facility level, and 
public ownership. ‡Proportion of the following medicines in stock: amlodipine, anastrozole, bisoprolol, furosemide, glimepiride, hydrochlorothiazide, letrozole, metformin, 
ramipril, salbutamol, simvastatin, tamoxifen, valsartan, and vildagliptin. §Average MPR for amlodipine, anastrozole, bisoprolol, furosemide, glimepiride, hydrochlorothiazide, 
letrozole, metformin, salbutamol, simvastatin, and tamoxifen. Ramipril (available at two facilities), valsartan (available at two facilities), and vildagliptin (available at one 
facility) were excluded because they do not have a published median reference price.
Table 5: Effect of Novartis Access on probability of availability and price of medicines at facilities





www.thelancet.com/lancetgh   Vol 7   April 2019 e498
group, and 58 (92%) facilities and 265 (89%) patients 
were retained in the control group (figure 1).
More than half of study facilities were dispensaries, 
while five were county hospitals (table 2). There was a 
near-even split between public and non-profit facilities. 
On average, less than 20% of the medicines were 
available at facilities at baseline, and the average MPR 
was around 3. Overall, intervention and control facilities 
had similar baseline stocks of medicines for non-
communicable diseases included in the Novartis Access 
portfolio, although intervention facilities were more 
likely to have furosemide and metformin than were 
control facilities.
Study patients were 58 years old on average and 
69% were women (table 3). More than two-thirds had 
hypertension, while 23% had type 2 diabetes and 19% had 
asthma. No patients with breast cancer were identified. 
Around 65% of patients had medicines to treat their 
disease in their home at baseline. Characteristics of 
patients were similar in the intervention and control 
groups.
Controlling for baseline value of the outcome, facility 
level, and public ownership, Novartis Access significantly 
increased the availability of amlodipine (adjusted odds 
ratio [aOR] 2·84, 95% CI 1·10 to 7·37; p=0·031) and 
metformin (aOR 4·78, 95% CI 1·44 to 15·86; p=0·011) at 
health facilities (table 4). There were no significant effects 
on the availability of other medicines at facilities (table 4) 
or on the mean probability of availability for all medicines 
in the Novartis Access portfolio (adjusted β [aβ] 0·05, 
95% CI –0·01 to 0·10; p=0·096; table 5). Similarly, there 
was no effect on the mean MPR of those medicines 
(aβ 0·48, 95% CI –1·12 to 0·72; p=0·500). Impact estimates 
from adjusted linear probability models (appendix) showed 
that Novartis Access significantly increased the prob-
ability that facilities had metformin (aβ 0·17, 95% CI 
0·05 to 0·29; p=0·006). The effect on the probability that 
facilities had amlodipine was not statistically significant 
(aβ 0·16, 95% CI –0·09 to 0·42; p=0·200).
Controlling for baseline value of the outcome, age, sex, 
marital status, education, household size, and household 
wealth, Novartis Access had no effect on the odds that 
patients had non-communicable disease medicines at 
home (aOR 0·83, 95% CI 0·44–1·57; p=0·569; table 6). 
Estimates from a model with sampling weights and a 
finite population correction were not meaningfully 
different (appendix). There was no effect when stratifying 
by hypertension (aOR 0·94, 95% CI 0·57–1·55; p=0·831), 
diabetes (aOR 1·08, 95% CI 0·09–13·35; p=0·951), and 
asthma (aOR 0·98, 95% CI 0·25–3·90; p=0·975). Impact 
estimates from adjusted linear probability models were 
consistent with the main results and showed no effect of 
Novartis Access on the probability that patients had non-
communicable disease medicines at home (appendix). 
Control Novartis Access ICC Unadjusted* Adjusted†
OR (95% CI) p value OR (95% CI) p value
Full sample (n=571) 208/265 (78%) 227/306 (74%) 0·10 0·85 (0·36–2·04) 0·721 0·83 (0·44–1·57) 0·569
Patients with hypertension (n=401) 155/184 (84%) 176/217 (81%) 0·10 0·84 (0·35–2·00) 0·692 0·94 (0·57–1·55) 0·831
Patients with diabetes (n=120) 48/57 (84%) 50/63 (79%) 0·13 0·91 (0·12–7·02) 0·926 1·08 (0·09–13·35) 0·951
Patients with asthma (n=117) 34/51 (67%) 43/66 (65%) 0·16 0·98 (0·25–3·82) 0·977 0·98 (0·25–3·90) 0·975
Data are n/N (%) unless otherwise stated. All regression models include random effects for study clusters (ie, counties). ICC=intracluster correlation coefficient. OR=odds ratio. 
*Controlling for baseline value of the outcome. †Controlling for baseline value of the outcome and a set of baseline demographics: age, sex, marital status, education, 
household size, and household wealth.
Table 6: Effect of Novartis Access on number of patients with medicines at home
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The intracluster correlation for the full sample of patients 
was 0·10.
Figure 2 describes the timeline of regulatory approval 
and first importation of Novartis Access-branded 
medicines into Kenya. Metformin was the first medicine 
to be approved in July, 2015, and imported in March, 
2016. Several other medicines were approved in October, 
2015, and of these amlodipine and salbutamol were the 
first to be imported in March, 2016, followed by 
glimepiride in April, 2016. Several additional medicines 
were approved and imported in late 2016 and early 2017. 
At the time of the 15 month follow-up in early 2018, two 
medicines—furosemide and ramipril—had not yet 
received regulatory approval.
Surveillance data on stock of Novartis Access-branded 
medicines show that amlodipine was the first medicine 
available at health facilities in intervention counties, in 
December, 2016, followed by salbutamol in January, 2017 
(figure 3). Novartis Access-branded metformin and 
vildagliptin were first available in May, 2017, followed by 
glimepiride in July, 2017. Finally, valsartan was first 
available in October, 2017. The other medicines in the 
Novartis Access portfolio were not found at health 
facilities during the study period. By the time of the 
15 month follow-up, amlodipine was found at around 
12% of intervention facilities, while the other medicines 
were found at 3–5% of facilities.
There was county-level variation in uptake of Novartis 
Access-branded medicines at health facilities (figure 4). 
Nyeri had the greatest uptake, with an average of 
0·64 offerings per facility. Kwale had more than 
0·43 offerings per facility, while West Pokot and Makueni 
had less (0·10 and 0·04 offerings per facility, respectively). 
At follow-up, two facilities in one control county were 
found to have one Novartis Access-branded medicine 
each, suggesting minor contamination in the study 
design. Using county-level variation in uptake of Novartis 
Access-branded medicines to estimate as-treated effects 
(table 7), we found that greater uptake was not significantly 
associated with household availability.
During qualitative interviews, fewer than 5% of health 
facility staff indicated that they had heard of Novartis 
Access from at least one source outside of the study. 
Sources that were mentioned included conversations 
with local medicine suppliers, printed brochures, and 
professional workshops.
Discussion
We investigated the effect of Novartis Access on 
availability and price of medicines for non-communicable 
diseases at health facilities and homes in eight counties 
in Kenya. After 15 months, the programme had a positive 
effect on availability of amlodipine and metformin at 
facilities, but had no effect on availability of the other 
medicines in the Novartis Access portfolio. The effect 
estimates for amlodipine and metformin are consistent 
with stock levels of Novartis Access-branded versions of 
those medicines found at intervention facilities at follow-
up. We found no effect on the price of medicines at 
health facilities, or on the availability of medicines at 
households. To our knowledge, this trial is the first 
randomised assessment of the impact of a pharma-
ceutical industry-led access to medicines programme.21 
This study also contributes to ongoing discussions on 
the role of measurement and transparency in establishing 
accountability for private sector social programmes.22,23
Aspects of the market for medicines for non-
communicable diseases in Kenya could have limited 








































































Figure 4: County-level uptake of Novartis Access medicines
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uptake of Novartis Access-branded medicines by health 
facilities and patients. First, the Novartis Access brand was 
new in the country and there was probably little awareness 
of the programme. During qualitative interviews 
conducted with facility staff at follow-up, less than 
5% indicated having heard about Novartis Access from 
sources outside of the study. Second, the timing of 
regulatory approval and importation probably contributed 
to the programme’s modest effect. The medicines found to 
have increased availability due to the programme—
amlodipine and metformin—were the first to be imported 
into Kenya following regulatory approval. Novartis Access-
branded versions of these medicines were found at 
facilities at follow-up. Amlodipine and metformin are used 
to treat hypertension and diabetes, respectively, the 
two most prevalent non-communicable diseases in the 
study population. Development of awareness of the 
programme among facility staff and patients requires 
time, and that process could not truly begin until the 
medicines were approved and in the country. It is possible 
that greater uptake of Novartis Access-branded medicines 
at facilities and larger overall effects would be found over a 
longer study period. Third, the medicines included in the 
programme portfolio were not necessarily the most in-
demand medicines used to treat the diseases being 
targeted. For example, at baseline a large proportion of 
hypertension patients reported using nifedipine to treat 
their condition, a medicine which is not included in the 
portfolio, and few reported using amlodipine, which is 
included.24 Similarly, beclometasone is the recommended 
treatment for most asthma cases but is not included 
in the programme portfolio. Several of the medicines 
(eg, bisoprolol, ramipril, valsartan, and simvastatin) were 
not available even at well stocked hospital pharmacies. 
County-level variation in medicine procurement and 
distribution practices, and patient disease burden and 
demand for treatment, might have contributed to obser ved 
variation in facility-level availability of programme 
medicines.25 Fourth, while Novartis Access aimed to 
provide medicines at a reduced price, $1 per treatment per 
month is not necessarily a bargain for some of the included 
medicines. For some of the medicines in the portfolio, 
$1 per treatment per month is well above the international 
median reference price.15 Fifth, the decision to distribute 
Novartis Access medicines solely through MEDS to public 
and non-profit facilities could have inhibited household 
uptake, as previously published evidence from the baseline 
survey shows that most participants regularly purchase 
their medicines at private sector outlets.26
Contradictions between the essential medicines list 
(EML) and the standard treatment guidelines (STGs) in 
Kenya might have inhibited uptake of Novartis Access, 
and contributed to low availability of non-communicable 
disease medicines included in the programme portfolio 
and overall.27 The Kenya National EML states that most 
non-communicable disease medicines should only be 
available at subdistrict hospitals and higher level 
facilities28 while local STGs do not restrict the 
management of common non-communicable diseases to 
specific levels of care.29–31 County procurement processes 
are largely guided by the EML, which might have 
contributed to low availability at lower-level facilities 
where many patients reported purchasing non-com-
municable disease medicines. Furthermore, some 
medicines in the Novartis Access portfolio—bisoprolol, 
glimepiride, ramipril, valsartan, and vildagliptin—are 
not included in the Kenya National EML, which could 
have limited purchasing by counties. Availability of 
essential medicines in Kenya is higher at private sector 
outlets than at public and non-profit outlets.32
There were important limitations to this work. First, 
given the regulatory complexity of the programme and 
the newness of the Novartis Access brand in Kenya, the 
15 month study period was probably insufficient to 
observe the full effect of the programme. A year 2 follow-
up assessment is planned, although Novartis Access will 
be altered in the second year and there will not be an 
opportunity to evaluate the programme in its current 
design over a longer time period. Second, our household 
sample was restricted to patients who had been 
diagnosed and were prescribed medicines for their non-
communicable disease, and as a result our measure of 
household availability did not account for those who 
might have had a non-communicable disease and 
needed medicines but who were undiagnosed. As a 
result, our measure of availability should not be 
interpreted as an overall measure of access. Third, 
counties in Kenya that purchased less than $100 000 
worth of medicines from MEDS in the year before 
baseline were excluded from the study. This factor might 
limit the generalisability of our findings. Counties that 
purchase greater volumes of medicines from MEDS as 
compared to KEMSA might have larger networks of 
faith-based health facilities and outlets, which could 
modify the effect of the programme. Fourth, the esti-
mated intracluster correlation for the primary household 
outcome (0·10) was higher than we assumed in the 
initial power calculation (0·05). In addition, we were not 
able to enrol the target sample size due to low prevalence 
of diagnosed non-communicable diseases in three 
Unadjusted* Adjusted†
OR (95% CI) p value OR (95% CI) p value
Full sample (n=571) 1·05 (0·97–1·13) 0·243 1·03 (0·97–1·10) 0·326
Patients with hypertension (n=401) 1·02 (0·94–1·11) 0·600 1·00 (0·93–1·08) 0·936
Patients with diabetes (n=120) 1·13 (0·96–1·33) 0·139 1·93 (0·87–4·29) 0·105
Patients with asthma (n=117) 1·19 (0·91–1·55) 0·197 1·19 (0·86–1·66) 0·286
The independent variable is the number of Novartis Access offerings in the county. All regression models include 
random effects for study clusters (ie, counties). OR=odds ratio. *Controlling for baseline value of the outcome. 
†Controlling for baseline value of the outcome and a set of baseline demographics: age, sex, marital status, education, 
household size, and household wealth.
Table 7: As-treated analysis of household availability at 15 month follow-up
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counties. Both of these factors contributed to lower 
statistical power than anticipated. Fifth, we estimated 
facility-level effect across all 14 medicines included in 
the Novartis Access portfolio, and when considered 
together the number of tests has an increased potential 
for at least one false-positive result. It might be 
appropriate to apply the Bonferroni correction and 
consider the critical p value threshold for these tests to 
be 0·003, in which case all facility-level effect estimates 
are non-significant. Sixth, the nature of Novartis Access 
necessitated county-level randomisation which limited 
the number of clusters that could be feasibly included in 
the study. While the baseline balance shown in table 1 
suggests that the study groups were quite comparable, 
we are not able to describe historical trends which would 
further confirm the internal validity of the study. The 
baseline imbalance in availability of metformin at 
facilities, although controlled for in the main regression 
analysis, could indicate different historical trends across 
groups which could be a source of bias. Finally, a 
substantial number of respondents could not accurately 
recall medicine prices or expend itures, and these 
outcomes were excluded from the analysis due to 
missing data. Asking respondents at baseline to obtain 
and keep receipts for all medicine purchases during the 
study period could be an alternative approach that yields 
better data in future studies.
This paper is, to our knowledge, the first to present 
experimental evidence on the effect of an industry-led 
access-to-medicines programme.21 The UN has recog-
nised the key role that the pharmaceutical industry 
should play in the effort to achieve universal health 
coverage globally.8 While we found that Novartis Access 
had little effect in its first year in Kenya, Novartis’s 
commitment to rigorous measurement and transparent 
reporting should serve as a standard for other industry 
efforts in this area.22,23 Access programmes operate within 
complex health systems and reducing the wholesale 
price of medicines might not always or immediately 
translate to improved patient access. Programme 
planners should adopt a health systems perspective 
and consider imple mentation challenges from project 
inception. Our findings underscore the need for more 
evaluation of industry-led access programmes. The 
evidence generated by this study will inform Novartis’s 
efforts to improve their programme going forward. The 
study also contributes to the public evidence base on 
strategies for improving access to medicines globally.
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